- Research & Development
- About us
- Invest in us
- Malaria & medicines
Research & Development
"Hundreds of dedicated experts and partner organizations have teamed up with MMV to build the largest pipeline of antimalarials in history."
Dr Dennis Schmatz,
Chair of Drug Discovery, MMV ESAC
Existing antimalarials have complex dosing regimes and target mainly falciparum malaria. MMV is seeking both a one-dose cure for falciparum malaria and a radical cure of vivax (relapsing) malaria.
Emerging drug resistance to artemisinin is a warning sign that we urgently need new classes of antimalarials. MMV is working to find ways to overcome resistance to current and future medicines.
New medicines that block the transmission of the parasite from patient to patient are vital if we are to defeat malaria. MMV is working to accelerate the development of these medicines.